# Virtue Diagnostics

> Virtue Diagnostics is a platform-based in vitro diagnostics (IVD) company headquartered in Singapore, with manufacturing in Suzhou, China and clinical operations in Beijing. Founded in 2019, it develops affordable diagnostic instruments and reagents across chemiluminescence, clinical chemistry, hematology, clinical mass spectrometry, multiplex immunohistochemistry (mIHC) and molecular diagnostics, aiming to serve patients through every stage of disease - from early screening and diagnosis to treatment monitoring and minimal residual disease management. Its strategy centers on localized innovation and expansion in emerging markets including China, Singapore, Brazil, Indonesia and the Philippines. The company closed a US$100 million Series B round in January 2022 led by Sequoia China and Morningside Ventures.

- **Founded:** 2019
- **Headquarters:** Singapore
- **Founders:** Johnson Zhang (Chief Executive Officer)
- **Team size:** ~46 employees (reported)
- **Products:** Clinical Mass Spectrometry, Chemiluminescence Immunoassay, Multiplex Immunohistochemistry (mIHC) / Digital Pathology, Molecular Diagnostics, Clinical Chemistry & Hematology
- **Notable:** Closed US$100 million Series B funding in January 2022, co-led by Sequoia China and Morningside Ventures., Launched a triple quadrupole clinical mass spectrometer with China NMPA approval in Q3 2021., Secured an exclusive China partnership with PerkinElmer for clinical mass spectrometry.

## Products & services

- **Clinical Mass Spectrometry** — Automated clinical mass spectrometry platform including a triple quadrupole mass spectrometer that received China NMPA approval and launched in Q3 2021; developed under an exclusive China partnership with PerkinElmer.
- **Chemiluminescence Immunoassay** — Automated chemiluminescence detection systems and reagent kits for immunoassay-based diagnostics across infectious disease, cancer and chronic disease markers.
- **Multiplex Immunohistochemistry (mIHC) / Digital Pathology** — Cost-effective multiplex immunohistochemistry and multiplex tissue-analysis solutions via the Panovue landscape-analysis pathology platform, acquired in 2021.
- **Molecular Diagnostics** — Molecular diagnostic assays and systems for infectious diseases and cancer, covering genomic and proteomic biomarker detection.
- **Clinical Chemistry & Hematology** — Automated clinical chemistry and hematology analyzers and reagents for routine laboratory testing.
- **Single-Cell Technology** — Single-cell analysis platform for biomarker discovery and advanced molecular biology applications.

## Achievements

- Closed US$100 million Series B funding in January 2022, co-led by Sequoia China and Morningside Ventures.
- Launched a triple quadrupole clinical mass spectrometer with China NMPA approval in Q3 2021.
- Secured an exclusive China partnership with PerkinElmer for clinical mass spectrometry.
- Acquired multiplex pathology company Panovue in 2021 to enter mIHC and digital pathology.
- Recognized with a 2023 Best IVD Enterprise award.

## Latest updates

- **2022-01** — Announced closing of US$100 million Series B round led by Sequoia China and Morningside Ventures, with ORIZA Holdings, Lilly Asia Ventures and PerkinElmer Ventures participating.
- **2021-09** — Launched NMPA-approved triple quadrupole clinical mass spectrometer.
- **2021** — Acquired Panovue, adding multiplex immunohistochemistry and digital-pathology capabilities.
- **2023** — Received a 2023 Best IVD Enterprise industry recognition.

## Links

- Website: https://virtuedx.com
- LinkedIn: http://www.linkedin.com/company/virtue-diagnostics-co-ltd

---

Profile page: https://yespress.io/virtue-diagnostics
Published by YesPress — https://yespress.io
Last updated: 2026-07-24